EXEL: Exelixis Inc Company Profile & Statistics

About

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET.

Info & Links

CEO

Michael M. Morrissey

Headquarters

1851 Harbor Bay Parkway
Alameda, CA 94502, UNITED STATES

Auditor

Ernst & Young LLP

Share holders

333

Employees

1,310

Exelixis Inc Statistics

Valuation Measures

Market Capitalization²

9.50B

Enterprise Value

9.25B

Enterprise Value/EBITDA(ttm)

16.78

Price to Earnings Ratio(ttm)

21.87

Price to Sales(ttm)

4.62

Price to Book(mrq)

4.23

Price to Cash(ytd)

43.74

Profitability

Gross Margin(ttm)

96.12%

Operating Margin(ttm)

22.15%

Profit Margin(ttm)

20.99%

Return on Equity(ttm)

20.99%

Return on Invested Capital(ttm)

21.38%

Return on Assets(ttm)

16.07%

Income Statement

Revenue(ttm)

2.08B

Revenue Per Share(ttm)

7.29

Gross Profit(ttm)

2.00B

EBITDA(ttm)³

550.89M

Net Income Available to Common(ttm)

466.92M

Diluted EPS(ttm)

1.56

Share Statistics

Beta (5Y Monthly)

0.52

52-Week Change

48.37%

S&P 500 52-Week Change

24.21%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

285.58M

Dividend Yield

0.00%

Float⁴

277.44M

% Held by Insiders

2.85%

% Held by Institutions

85.27%

Balance Sheet

Total Cash(mrq)

1.19B

Total Cash Per Share(mrq)

4.16

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

3.93%

Quick Ratio(mrq)

3.88%

Book Value Per Share(mrq)

7.96

Cash Flow

Operating Cash Flow Per Share(ytd)

1.58

Free Cash Flow(ytd)

407.50M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

EXEL

Exelixis Inc

Exelixis Inc Profile